Advertisement
ARCT vs NTLA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and NTLA is a StrongBuy.
ARCT's Stochastic Oscillator remains in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.712) is normal, around the industry mean (3.498). P/E Ratio (-3.108) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Aroon Indicator for NTLA shows an upward move is likely
NTLA's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 128 similar instances where the Aroon Indicator showed a similar pattern. In 109 of the 128 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NTLA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NTLA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (3.498). P/E Ratio (-3.398) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARCT | NTLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 57 | 60 | |
P/E GROWTH RATING 1..100 | 96 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (32) in the Pharmaceuticals Major industry is in the same range as NTLA (36) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NTLA’s over the last 12 months.
ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NTLA’s over the last 12 months.
ARCT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as NTLA (98) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NTLA’s over the last 12 months.
ARCT's Price Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as NTLA (60) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than ARCT’s over the last 12 months.
| ARCT | NTLA | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Advances ODDS (%) | 10 days ago 82% | 5 days ago 79% |
| Declines ODDS (%) | 1 day ago 88% | 12 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 81% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 0 green FA rating(s).
- ARCT’s FA Score: 1 green, 4 red.
- NTLA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).
- ARCT’s TA Score: 3 bullish, 6 bearish.
- NTLA’s TA Score: 3 bullish, 6 bearish.
Price Growth
ARCT (@Biotechnology) experienced а -9.83% price change this week, while NTLA (@Biotechnology) price change was -4.95% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.
Reported Earning Dates
NTLA is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+2.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARCT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CRSP. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | -9.34% | ||
| CRSP - ARCT | 52% Loosely correlated | -6.84% | ||
| BCYC - ARCT | 52% Loosely correlated | -6.50% | ||
| NTLA - ARCT | 51% Loosely correlated | -7.54% | ||
| EDIT - ARCT | 50% Loosely correlated | -10.08% | ||
| NVAX - ARCT | 50% Loosely correlated | -12.22% | ||
More | ||||